Systemic scleroderma+1
RecruitingA study to evaluate the safety and effectiveness of QEL-005 in patients with diffuse cutaneous systemic sclerosis and difficult to treat rheumatoid arthritis
A study to evaluate the safety and effectiveness of QEL-005 in patients with diffuse cutaneous systemic sclerosis and difficult to treat rheumatoid arthritis
- Disease:Systemic sclerodermaRheumatoid arthritis
- Substances:QEL-005
Germany- Participants:18–64 years · 65+ years
- Substances:QEL-005
- Sponsor:Quell Therapeutics Limited




